Información del artículo
El trasplante de órgano sólido se ha establecido como una opción importante para el tratamiento de muchas enfermedades. La osteoporosis es una complicación común tras un trasplante de órgano sólido y está relacionada con un incremento en la incidencia de fracturas y de la morbilidad en los receptores del trasplante. En esta presentación se pretende revisar los factores implicados en la patogenia de esta importante complicación, así como la evaluación, la prevención y las opciones posibles de tratamiento en la osteoporosis postrasplante.
Palabras clave:
Osteoporosis postrasplante
Inmunosupresión
Factores de riesgo
Tratamiento
Solid organ transplantation has become an established treatment option for many diseases. Osteoporosis is a common complication after solid organ transplantation and is associated with an increased incidence of fractures and related morbidity in transplant recipients. The present article reviews the factors contributing to the pathogenesis of this serious complication. The evaluation and prevention of post-transplantation osteoporosis, as well as the available treatment options, are also discussed.
Key words:
Post-transplantation osteoporosis
Immunosuppression
Risk factors
Treatment
El Texto completo está disponible en PDF
Bibliografía
[1.]
E. Shane, M. Rivas, R.B. Staron, S.J. Silverberg, M.J. Seibel, J. Kuiper, et al.
Fracture after cardiac transplantation: A prospective longitudinal study.
J Clin Endocrinol Metab, 81 (1996), pp. 1740-1746
[2.]
E. Meys, F. Fontages, N. Fourcade, A. Thomasson, M. Pouyet, P.D. Delmas.
Bone loss after orthotopic liver transplantation.
Am J Med, 97 (1994), pp. 445-450
[4.]
P.D. Delmas.
Osteoporosis in patients with organ transplants:a neglected problem.
Lancet, 357 (2001), pp. 325-326
[5.]
G. Leidig-Bruckner, S. Hosch, P. Dodidou, D. Ritschel, C. Conradt, C. Klose, et al.
Frecuency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study.
Lancet, 357 (2001), pp. 342-347
[6.]
N. Guañabens, A. Monegal.
Formas especiales de osteoporosis: osteoporosis asociada al trasplante.
Manual práctico de osteoporosis y enfermedades del metabolismo mineral, pp. 279-284
[7.]
N. Guañabens.
Osteoporosis y trasplante de órganos sólidos.
Med Clin (Barc), 114 (2000), pp. 772-773
[8.]
M.A. Rodino, E. Shane.
Osteoporosis after organ transplantation.
Am J Med, 104 (1998), pp. 459-469
[9.]
E. Shane.
Transplantation osteoporosis.
Primer of the metabolic bone diseases and disorders of mineral metabolism, 4.a ed, pp. 296-301
[10.]
D. Thiebaud, M.A. Krieg, D. Gillard-Berguer, A.F. Jacquet, J.J. Goy, P. Burckhardt.
Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation.
Eur J Clin Invest, 26 (1996), pp. 549-555
[11.]
N.M. Maalouf, E. Shane.
Clinical Review: Osteoporosis after solid organ transplantation.
JCEM, 90 (2005), pp. 2456-2465
[12.]
J.E. Compston.
Osteoporosis after liver transplantation.
Liver Transplant, 9 (2003), pp. 321-330
[13.]
E. Shane, S.J. Silverberg, D. Donovan, A. Papadopoulos, R.B. Staron, V. Addesso, et al.
Osteoporosis in lung transplantation candidates with end-stage pulmonary disease.
Am J Med, 101 (1996), pp. 262-269
[14.]
A.H. Lee, R.L. Mull, G.F. Keenan, P.E. Callegari, M.K. Dalinka, D.M. Mancini, et al.
Osteoporosis and bone morbidity in cardiac transplant recipients.
Am J Med, 96 (1994), pp. 35-41
[15.]
G. Elder.
Pathophysiology and recent advances in the management of renal osteodystrophy.
J Bone Miner Res, 17 (2002), pp. 2094-2105
[16.]
K.A. Hruska, S.L. Teitelbaum.
Renal osteodystrophy.
N Engl J Med, 333 (1995), pp. 166-175
[17.]
A.M. Ball, D.L. Gillen, D. Sherrard, N.S. Weiss, S.S. Emerson, S.L. Seliger, et al.
Risk of hip fracture among dialisis and renal transplant recipients.
JAMA, 288 (2002), pp. 3014-3018
[18.]
A.M. Alem, D.J. Sherrard, D.L. Gillen, N.S. Weiss, S.A. Beresford, S.R. Heckbert, et al.
Increased risk of hip fracture among patients with end-stage renal disease.
Kidney Int, 58 (2000), pp. 396-399
[19.]
C.O. Stehman-Breen, D.J. Sherrard, A.M. Alem, D.L. Gillen, S.R. Heckbert, C.S. Wong, et al.
Risk factors for hip fracture among patients with end-stage renal disease.
Kidney Int, 58 (2000), pp. 2200-2205
[20.]
E. Canalis.
Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis.
J Clin Endocrinol Metab, 81 (1996), pp. 3441-3447
[21.]
Y. Suzuki, Y. Ichikawa, E. Saito, M. Homma.
Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy.
Metabolism, 32 (1983), pp. 151-156
[22.]
D.V. Kimberg, R.D. Baerg, E. Gershon, R.T. Graudusius.
Effect of cortisone treatment on the active transport of calcium by the small intestine.
J Clin Invest, 50 (1971), pp. 1309-1321
[23.]
E. Canalis, A.M. Delany.
Mechanisms of glucocorticoid action in bone.
Ann NY Acad Sci, 966 (2002), pp. 73-81
[24.]
B. Danneskiold-Samsoe, G. Grimby.
The influence of prednisone on the muscle morphology and muscle enzymes in patients with rheumatoid arthritis.
Clin Sci, 71 (1986), pp. 693-701
[25.]
S. Matsuda, S. Koyasu.
Mechanisms of action of cyclosporine.
Immunopharmacology, 47 (2000), pp. 119-125
[26.]
S. Epstein.
Post-transplantation bone disease: the role of inmunosuppressive agents on the skeleton.
J Bone Miner Res, 11 (1996), pp. 1-7
[27.]
M. Schlosberg, C. Movsowitz, S. Epstein, F. Ismail, M.D. Fallon, S. Thomas.
The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat.
Endocrinology, 124 (1989), pp. 2179-2184
[28.]
C. Movsowitz, S. Epstein, M. Fallon, F. Ismail, S. Thomas.
Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration.
Endocrinology, 123 (1988), pp. 2571-2577
[29.]
W.M. Bennett, A. DeMattos, M.M. Meyer, T. Andoh, J.M. Barry.
Chronic cyclosporine nephropathy: the Achilles’ heel of immunosuppressive therapy.
Kidney Int, 50 (1996), pp. 1089-1100
[30.]
A. Monegal, M. Navasa, N. Guanabens, P. Peris, F. Pons, M.J. Martinez de Osaba, et al.
Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A.
Calcif Tissue Int, 68 (2001), pp. 83-86
[31.]
G.A. Smallwood, D. Burns, C.G. Fasola, A.C. Steiber, T.G. Heffron.
Relationship between inmunosuppression ans osteoporosis in an outpatient liver transplant clinic.
Transplant Proc, 37 (2005), pp. 1910-1911
[32.]
I.R. Dissanayake, G.R. Goodman, A.R. Bowman, Y. Ma, S. Pun, W.S. Jee, et al.
Mycophenolate mofetil: a promising new immunosuppressant that does not cause bone loss in the rat.
Transplantation, 65 (1998), pp. 275-278
[33.]
I. Joffe, I. Katz, S. Sehgal, F. Bex, Y. Kharode, J. Tamasi, et al.
Lack of change of cancellous bone volume with short-term use of the new inmunosuppressant rapamycin in rats.
Calcif Tissue Int, 53 (1993), pp. 45-52
[34.]
H.P. Bryer, J.A. Isserow, E.C. Armstrong, G.N. Mann, B. Rucinski, F.J. Buchinsky, et al.
Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat.
J Bone Miner Res, 10 (1995), pp. 132-138
[35.]
E. Shane, M. Rivas, D.J. McMahon, R.B. Staron, S.J. Silverberg, M.J. Seibel, et al.
Bone loss and turnover after cardiac transplantation.
J Clin Endocrinol Metab, 82 (1997), pp. 1497-1506
[36.]
B. Julian, L. Quarles, K. Niemann.
Musculoskeletal complications after renal transplantation: Pathogenesis and treatment.
Am J Kidney Dis, 19 (1992), pp. 99-120
[37.]
A. Torres, A.P. Rodriguez, M.T. Concepcion, S. Garcia, M. Rufino, B. Martin, et al.
Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations.
Nephrol Dial Transplant, 13 (1998), pp. 94-97
[38.]
A. Monegal, M. Navasa, N. Guañabens, P. Peris, F. Pons, M.J. Martinez de Osaba, et al.
Bone disease after liver transplantation:a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics.
Osteoporosis Int, 12 (2001), pp. 484-492
[39.]
B.A. Julian, D.A. Laskow, J. Dubovsky, E.V. Dubovsky, J.J. Curtis, L.D. Quarles.
Rapid loss of vertebral mineral density after renal transplantation.
N Engl J Med, 325 (1991), pp. 544-550
[40.]
E. Shane, A. Papadopoulos, R.B. Staron, V. Addesso, D. Donovan, C. McGregor, et al.
Bone loss and fracture after lung transplantation.
Transplantation, 68 (1999), pp. 220-227
[41.]
V. Pichette, A. Bonnardeaux, L. Prudhomme, M. Gagne, J. Cardinal, D. Ouimet.
Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study.
Am J Kidney Dis, 28 (1996), pp. 105-114
[42.]
C. Marsh.
Calcineurin-sparing or steroid-sparing inmunosuppression in renal transplantation.
Curr Opin Organ Transplant, 7 (2002), pp. 145-156
[43.]
G. Martinez, R. Gomez, E. Jodar, C. Loinaz, E. Moreno, E. Hawkins.
Long-term follow-up of bone mass after orthotopic liver transplantation: effect of steroid withdrawal from the inmunosuppressive regimen.
Osteoporosis Int, 13 (2002), pp. 147-150
[44.]
E. Nowacka-Cieciura, M. Durlik, T. Cieciura, M. Talalaj, K. Kukula, D. Lewandowska, et al.
Positive effect of steroid withdrawal on bone mineral density in renal allograft recipients.
Transplant Proc, 33 (2001), pp. 1273-1277
[45.]
A. Cohen, P. Sambrook, E. Shane.
Management of bone loss after organ transplantation.
J Bone Miner Res, 19 (2004), pp. 1919-1932
[46.]
D. Kovac, J. Lindic, A. Kandus, A.F. Bren.
Prevention of bone loss in kidney graft recipients.
Transplant Proc, 33 (2001), pp. 1 144-1145
[47.]
M. Hommann, K. Abendroth, G. Lehmann, N. Patzaz, A. Kornberg, R. Voigt, et al.
Effect of transplantation on bone; osteoporosis after liver and multivisceral transplantation.
Transplant Proc, 34 (2002), pp. 2296-2298
[48.]
R.M. Aris, G.E. Lester, J.B. Renner, A. Winders, A. Denene Blackwood, R.K. Lark, et al.
Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation.
Am J Respir Crit Care Med, 162 (2000), pp. 941-946
[49.]
B.A. Crawford, C. Kam, J. Pavlovic, K. Byth, D.J. Handelsman, P.W. Angus, et al.
Zoledronic acid prevents bone loss after liver transplantation:a randomised, double-blind, placebo-controlled trial.
Ann Intern Med, 144 (2006), pp. 239-248
[50.]
E. Shane, V. Addesso, P.B. Namerow, D.J. McMahom, S.H. Lo, R.B. Staron, et al.
Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
N Engl J Med, 350 (2004), pp. 767-776
[51.]
M. Maricic.
Glucocorticoid-induced osteoporosis :treatment options and guidelines.
Curr Osteoporos Rep, 3 (2005), pp. 25-29
[52.]
M.A. Valero, C. Loinaz, L. Larrodera, M. León, E. Moreno, F. Hawkins.
Calcitonin and biphosphonates treatment in bone loss after liver transplantation.
Calcif Tissue Int, 57 (1995), pp. 15-19
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición
